New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:03 EDTADHDAlcobra submits INDA with FDA for Phase III trial
Alcobra announced the submission of an Investigational New Drug Application with the U.S. FDA to initiate a Phase III clinical trial with MG01CI. "With the submission of this IND, the company has achieved an additional major milestone in its development program of MG01CI for ADHD and other cognitive disorders. Given the positive results in our two previous Phase II studies in adults with ADHD we look forward to working closely with the FDA to meet the remaining requirements necessary to bring this therapy to the market," said Dr. Yaron Daniely, president & CEO of Alcobra.
News For ADHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
06:02 EDTADHDStocks with implied volatility above IV index mean; SNSS ADHD
Subscribe for More Information
September 26, 2014
06:07 EDTADHDStocks with implied volatility above IV index mean; SNSS ADHD
Stocks with implied volatility above IV index mean; Sunesis (SNSS) 329, Alcobra (ADHD) 334 according to iVolatility.
September 23, 2014
10:37 EDTADHDAlcobra October volatility elevated into Phase III trial data
Alcobra October call option implied volatility is at 347, November is at 249, December is at 223; compared to its 15-week average of 191 according to Track Data, suggesting large price movement into release of data from the first Phase III trial of MDX in Adult ADHD.
September 22, 2014
07:12 EDTADHDAlcobra October volatility elevated into Phase III trial data
Subscribe for More Information
September 19, 2014
16:24 EDTADHDAlcobra announces completion of all patient visits in phase 3 MDX trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use